# SOCS1

Source: https://onco.cc/targets/socs1/  
OnCo record `socs1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SOCS1 (Suppressor of cytokine signalling 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma and Rectal cancer.

## Summary

Essential negative regulator of type I and type II interferon (IFN) signalling, as well as that of other cytokines, including IL2, IL4, IL6 and leukaemia inhibitory factor (LIF). Down-regulates cytokine signalling by inhibiting the JAK/STAT signalling pathway. Acts by binding to JAK proteins and to IFNGR1 and inhibiting their kinase activity.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.49 (direct and indirect evidence; datatypes literature 0.99, animal model 0.51, genetic association 0.04, somatic mutation 0.74). IntOGen calls it a driver in 5 cohorts (3 activating, 2 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma, Rectal Adenocarcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: suppressor of cytokine signaling 1; Suppressor of cytokine signaling 1; SOCS-1; SSI-1; TIP3; Cish1
- Tags: cancer-genes-wave
- Symbol: SOCS1
- Class: oncogene
- Biology: Essential negative regulator of type I and type II interferon (IFN) signalling, as well as that of other cytokines, including IL2, IL4, IL6 and leukaemia inhibitory factor (LIF). Down-regulates cytokine signalling by inhibiting the JAK/STAT signalling pathway. Acts by binding to JAK proteins and to IFNGR1 and inhibiting their kinase activity. In vitro, suppresses Tec protein-tyrosine activity. Regulates IFN-gamma (IFNG)-mediated sensory neuron survival. Probable substrate recognition component of an ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Location: Nucleus; Cytoplasmic vesicle (UniProt). Locus 16p13.13 (HGNC).
- Where found: Non-Hodgkin lymphoma: Open Targets association 0.68 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL); Diffuse large B-cell lymphoma: Open Targets association 0.63 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease; Rectal cancer: IntOGen driver in 1 cohort (READ)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 3 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:19383: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19383
- UniProt O15524: https://www.uniprot.org/uniprotkb/O15524/entry
- NCBI Gene 8651: https://www.ncbi.nlm.nih.gov/gene/8651
- Ensembl ENSG00000185338: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185338

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)

---
JSON: https://onco.cc/api/v1/entities/socs1.json